KIF20A and neoplasm: An early finding that KIF20A expression was largely restricted to malignant tissues, particularly pancreatic cancer, with minimal expression in most adult normal tissues spurred Imai et al. to hypothesize that peptides derived from MKLP2 could be tumour-associated antigens (TAAs) and targets for cancer immunotherapy [98].